DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS
Granted: July 3, 2014
Application Number:
20140186515
Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any…
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
Granted: July 3, 2014
Application Number:
20140186440
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
Granted: May 15, 2014
Application Number:
20140135395
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
METHOD OF TREATING POST-SURGICAL ACUTE PAIN
Granted: April 17, 2014
Application Number:
20140107210
A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: March 13, 2014
Application Number:
20140072623
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
PHARMACEUTICAL COMPOSITIONS FOR EXTENDED RELEASE OF AZO-BONDED 5-AMINOSALICYLIC ACID COMPOSITIONS
Granted: March 6, 2014
Application Number:
20140066411
Gastric retentive dosage forms for sustained release of an azo-bonded prodrug of 5-aminosalicylic acid (5-ASA) are described which may allow once- or twice-daily dosing for both acute and long-term treatment of inflammatory bowel disorders. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.
COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL MOTILITY DYSFUNCTION
Granted: November 28, 2013
Application Number:
20130316002
Extended release oral dosage forms for the treatment of gastrointestinal motility disorders are described. Active agents which are small molecules, peptides, peptide analogs, and peptide mimetics are formulated for optimal release in the GI tract of subjects with GI motility dysfunction. Methods of treatment using the dosage forms are also described.
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: August 29, 2013
Application Number:
20130224289
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
SHELL-AND-CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE
Granted: June 27, 2013
Application Number:
20130164377
Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.
METHODS FOR TREATING VASOMOTOR SYMPTOMS USING GABA ANALOGS IN A GASTRIC RETENTIVE DOSAGE FORM
Granted: June 20, 2013
Application Number:
20130158121
Methods for treating vasomotor symptoms associated with menopause are described.
GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT
Granted: June 13, 2013
Application Number:
20130149379
Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a…
GASTRIC RETENTIVE GABAPENTIN DOSAGE FORMS AND METHODS FOR USING SAME
Granted: May 9, 2013
Application Number:
20130116320
Provided is a method of treating a patient suffering from a pain state by administering to the patient a gastric retentive dosage form of gabapentin that is capable of administration in once-daily or twice daily dosing regimens. By reducing the need to administer gabapentin from the thrice-daily administrations characteristic of immediate release gabapentin, the gastric retentive gabapentin dosage forms provided herein have the advantages of improving patient compliance for gabapentin…
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
Granted: December 20, 2012
Application Number:
20120321713
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
Gastric Retained Gabapentin Dosage Form
Granted: November 15, 2012
Application Number:
20120289601
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: November 8, 2012
Application Number:
20120282307
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS
Granted: October 18, 2012
Application Number:
20120263792
Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing lull access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any…
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
Granted: June 14, 2012
Application Number:
20120148671
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF A NON-OPIOID ANALGESIC AND AN OPIOID ANALGESIC
Granted: May 31, 2012
Application Number:
20120136022
Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE
Granted: May 24, 2012
Application Number:
20120128735
A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.
GASTRIC RETENTIVE DOSAGE FORMS FOR EXTENDED RELEASE OF ACAMPROSATE INTO THE UPPER GASTROINTESTINAL TRACT
Granted: March 29, 2012
Application Number:
20120077878
Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple…
